Dr..Meghana Tanwar
To evaluate the factors affecting the efficacy of Botulinum toxin type A in facial dystonias.
METHODS: 27 patients of facial dystonias, treated with the toxin, were followed up over a period of 5 years or till they discontinued our treatment. A correlation analysis was done to identify factors which were associated with longer symptom-free intervals. P<0.05 was considered statistically significant. RESULTS: The mean number of symptom-free days with doses of 20, 22.5, 25, 30 and 50U was 102.1±44.7, 132.4±35.3, 147.2±61.6, 124.4±55.1 and 142.4±59.7 respectively. The commonest complication was lagophthalmos(26.3%; n=20). There was no correlation between the dose and the symptom-free interval(R=0.12; P=0.31). There was a statistically significant increase in the efficacy with each injection at doses of 22.5U(R=0.66; P=0.04). CONCLUSION: Botulinum toxin type A is safe and effective in the treatment of facial dystonias. It’s efficacy increases with each injection at a dose of 22.5U.
Leave a Comment